Contact
searchSearch
HMP Global
Login

Test Deciphera 2021

Recent News

News
Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma
06/01/2026
Emily Estrada
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the...
06/01/2026
Oncology
News
Ropeginterferon Shows Efficacy Across Treatment Lines and Mutation Subtypes in Essential Thrombocythemia
06/01/2026
Stephanie Holland
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from an integrated...
06/01/2026
Oncology
News
Asandeutertinib Demonstrates Superior Intracranial Efficacy in EGFR-Mutated NSCLC
05/31/2026
Emily Estrada
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA...
05/31/2026
Oncology
News
BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
05/31/2026
Stephanie Holland
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib,...
05/31/2026
Oncology
News
HARMONi-6 Trial Positions Ivonescimab Plus Chemotherapy as New First-Line Standard of Care in Squamous NSCLC
05/31/2026
Emily Estrada
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial...
05/31/2026
Oncology
News
Metronomic Chemo-Immunotherapy Improves Survival in Metastatic Head and Neck Cancer
05/31/2026
Stephanie Holland
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial...
05/31/2026
Oncology
News
Adding Sintilimab to Adjuvant Capecitabine Fails to Improve PFS in High-Risk Nasopharyngeal Carcinoma
05/31/2026
Stephanie Holland
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from a randomized phase 2 trial demonstrated that adding sintilimab to adjuvant capecitabine did not significantly improve PFS in patients with locoregionally advanced nasopharyngeal carcinoma who experienced a suboptimal response to...
Results from a randomized phase...
05/31/2026
Oncology
News
Talazoparib Plus Enzalutamide Reduces Risk of Radiographic Progression in HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3...
05/30/2026
Oncology
News
Omitting Axillary Lymph Node Dissection Appears Safe in Node-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC trial demonstrated that omitting axillary lymph node dissection following a positive sentinel lymph node biopsy appears safe in patients with early-stage breast cancer.
Results from the phase 3 SENOMAC...
05/30/2026
Oncology
News
Anbenitamab Demonstrates Significant Neoadjuvant Benefit in HER2-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial...
05/30/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use